Peginterferon alfa-2a in patients with chronic hepatitis C

New England Journal of Medicine

Volumn 343, Issue 23, 2000, Pages 1666-1672

  Zeuzem, Stefan ^a   Feinman, S Victor ^b   Rasenack, Jens ^c   Heathcote, E Jenny ^d   Lai, Ming Yang ^e   Gane, Edward ^f   O'Grady, John ^g   Reichen, Jürg ^h   Diago, Moises ⁱ   Lin, Amy ^j   Hoffman, Joseph ^j   Brunda, Michael J ^j  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF FREIBURG   (Germany)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f MIDDLEMORE HOSPITAL   (New Zealand)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ Hospital General Universitario   (Spain)

^j HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MACROGOL; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; POLYETHYLENE GLYCOLS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0034619946     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200012073432301     Document Type: Article

References (20)

1. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
2. Meta-analysis of interferon rancomized trials in the treatment of viral hepatitis C: Effects of dose and duration
3. Therapy of hepatitis C: Interferon alfa-n1 trials
4. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus α2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus
5. Interferon alfa-2b alone arin combination with ribavirin as initial treatment for chronic hepatitis C
6. Clinical pharmacokinetics of interferons
7. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
8. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
9. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
10. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects
11. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects
12. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the phannacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
13. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
14. An alternative to the use of two-sided tests in clinical trials
15. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
16. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
17. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C
18. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
19. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis